Here are four notes:
1. Analysts expect the company’s EPS growth to fall 14.29 percent.
2. During the last trading session, NuVasive stock increased 1.73 percent.
3. The shares have underperformed the S&P 500 by 2.05 percent.
4. NuVasive shares have decreased 13.06 percent since July 2015.
More articles on devices:
Dr. Rick Pospisil to offer carpal tunnel procedures — 5 points
NuVasive establishes new 52-week low: 4 points
Medtronic launches Valleylab FT10 energy platform: 4 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
